These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 39177875)

  • 1. Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems.
    Beraza-Millor M; Rodríguez-Castejón J; Del Pozo-Rodríguez A; Rodríguez-Gascón A; Solinís MÁ
    BioDrugs; 2024 Sep; 38(5):657-680. PubMed ID: 39177875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach.
    Coutinho MF; Santos JI; S Mendonça L; Matos L; Prata MJ; S Jurado A; Pedroso de Lima MC; Alves S
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.
    Seregin SS; Amalfitano A
    Curr Pharm Des; 2011; 17(24):2558-74. PubMed ID: 21774776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving therapies in neuronopathic LSDs: opportunities and challenges.
    Rajan DS; Escolar ML
    Metab Brain Dis; 2022 Oct; 37(7):2245-2256. PubMed ID: 35442005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.
    Macauley SL
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1(Suppl 1):639-48. PubMed ID: 27491211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for lysosomal storage disorders.
    Barranger JM; Novelli EA
    Expert Opin Biol Ther; 2001 Sep; 1(5):857-67. PubMed ID: 11728220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders.
    Del Grosso A; Parlanti G; Mezzena R; Cecchini M
    Adv Drug Deliv Rev; 2022 Sep; 188():114464. PubMed ID: 35878795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study.
    Eskes ECB; Beishuizen CRL; Corazolla EM; van Middelaar T; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B
    Orphanet J Rare Dis; 2022 Oct; 17(1):383. PubMed ID: 36271424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of induced pluripotent stem cells in lysosomal storage diseases.
    Kido J; Nakamura K; Era T
    Mol Cell Neurosci; 2020 Oct; 108():103540. PubMed ID: 32828964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
    Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal storage diseases: current therapies and future alternatives.
    Leal AF; Espejo-Mojica AJ; Sánchez OF; Ramírez CM; Reyes LH; Cruz JC; Alméciga-Díaz CJ
    J Mol Med (Berl); 2020 Jul; 98(7):931-946. PubMed ID: 32529345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Trojan Horses for treating lysosomal storage diseases.
    Leal AF; Inci OK; Seyrantepe V; Rintz E; Celik B; Ago Y; León D; Suarez DA; Alméciga-Díaz CJ; Tomatsu S
    Mol Genet Metab; 2023 Nov; 140(3):107648. PubMed ID: 37598508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PATIENT-REPORTED OUTCOMES IN RARE LYSOSOMAL STORAGE DISEASES: KEY INFORMANT INTERVIEWS AND A SYSTEMATIC REVIEW PROTOCOL.
    Miller PA; Mulla SM; Adams-Webber T; Sivji Y; Guyatt GH; Johnston BC
    Int J Technol Assess Health Care; 2016 Jan; 32(6):393-399. PubMed ID: 28029334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal storage disorders: old diseases, present and future challenges.
    Klein AD; Futerman AH
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():59-63. PubMed ID: 24380123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for lysosomal storage diseases (LSDs) in large animal models.
    Haskins M
    ILAR J; 2009; 50(2):112-21. PubMed ID: 19293456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease.
    Abasolo I; Seras-Franzoso J; Moltó-Abad M; Díaz-Riascos V; Corchero JL; Pintos-Morell G; Schwartz S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1684. PubMed ID: 33314628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models.
    Ellinwood NM; Vite CH; Haskins ME
    J Gene Med; 2004 May; 6(5):481-506. PubMed ID: 15133760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review.
    Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A
    Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G; Pignata C; Vajro P; Salerno M
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.